Genzyme snags fast-track designation for Fabry drug; PTC advances a cancer treatment;

@FierceBiotech: ICYMI yesterday: Celgene bags a build-to-buy biotech in $485M cancer deal. Report | Follow @FierceBiotech

@JohnCFierce: Biogen CEO Scangos commits $2.5B to a high stakes Alzheimer's gamble. More | Follow @JohnCFierce

> Sanofi's ($SNY) Genzyme business scored the FDA's fast-track designation for GZ/SAR402671, a Phase II treatment for the rare Fabry disease. More

> PTC Therapeutics ($PTCT) kicked off a Phase I study for PTC596, an oral cancer treatment targeting the protein BMI1. News

> Cerulean Pharma ($CERU) picked up a fast-track nod for CRLX101, a nanoparticle-drug conjugate designed to treat renal cancer in combination with Roche's ($RHHBY) Avastin. Item

Medical Device News

@FierceMedDev: ICYMI yesterday: Two U.S. hospitals to test startup's novel medical device malware detection software. Article | Follow @FierceMedDev

@VarunSaxena2: FDA bans manufacturing of Medtronic's infusion pump, citing violation of quality system regs. News | Follow @VarunSaxena2

@EmilyWFierce: Scanadu ropes in $35M for smartphone tricorder diagnostic device. More | Follow @EmilyWFierce

> Belgian molecular Dx player Biocartis raises €100M to advance recent launch of Idylla system. Story

> 'Stealthy' Medina raises $6M in debt for cerebral aneurysm device after CE mark last fall. Article

Pharma News

@FiercePharma: Daiichi Sankyo has solid chance to pare debt, reinvest on Sun stake sale, Moody's says. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: Bayer to close a vet med plant in Missouri it bought from Teva. 130 workers to lose jobs. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Would any of you guys want to read a special report entitled "The secret first initials of biopharma CEOs and what they stand for"...? | Follow @CarlyHFierce

> Flush with Q1 success, Merck touts coming launches in hep C, lung cancer. Story

> It's official: Takeda to pay a 'bargain' $2.3B to settle Actos lawsuits. Article

Drug Delivery News

> Presage's multiple-cancer-drug injection device shows promising first-in-human results. Story

> Topical gel for migraine shows promise in trials, can penetrate transdermal barrier. Item

> 3M says its new intravenous port dressing will make drug delivery easier and fight off site infections. Report

> AbbVie's FDA-approved Duopa gel for Parkinson's skates through yearlong study. Story

> Generex announces second medical marijuana outlicensing deal for its drug delivery tech. Article

Pharma Manufacturing News

> Texas cancer center guilty of selling foreign-made Avastin. Item

> Wockhardt recalling all pre-ban products still in the U.S. More

> Mylan recalls injected cancer meds made for Pfizer. Story

> GSK licks Nicorette manufacturing problems; 'Minis' are back. Article

> Lilly's Elanco to unload former Novartis vax plant. News

Pharma Asia News

> Eisai, Nihon Medi-Physics plan work on dementia with Lewy bodies. Report

> India mulls adopting international standards on drug inspections, manufacturing. Story

> Cipla leans toward compromise in India court case over Onbrez from Novartis. More

> Japan's Panasonic joins Toshiba in rush to medical devices. Article

> Daiichi Sankyo has solid chance to pare debt, reinvest on Sun stake sale, Moody's says. Item

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.